Low serum galectin-3 concentrations are associated with insulin resistance in patients with type 2 diabetes mellitus

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Ohkura, Tsuyoshi ^a   Fujioka, Youhei ^a   Nakanishi, Risa ^a   Shiochi, Hideki ^a   Sumi, Keisuke ^a   Yamamoto, Naoya ^a   Matsuzawa, Kazuhiko ^a   Izawa, Shoichiro ^a   Ohkura, Hiroko ^a   Ueta, Etsuko ^a   Kato, Masahiko ^a   Miyoshi, Eiji ^b   Taniguchi, Shin Ichi ^a   Yamamoto, Kazuhiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Galectin 3; Insulin resistance; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GALECTIN 3; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; PROINSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; STEADY STATE; TEST MEAL; WAIST CIRCUMFERENCE;

EID: 84910628518     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-106     Document Type: Article

References (25)

1. Galectins: Structure, function and therapeutic potential. Yang RY, Rabinovich GA, Liu FT, Expert Rev Mol Med 2008 13 17 e39
2. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ, Ann Med 2011 43 60 68 10.3109/07853890.2010.538080 21189092
3. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, Schnitzbauer A, Schäffler A, Aslanidis C, Schölmerich J, Buechler C, J Clin Endocrinol Metab 2010 95 1404 1411 10.1210/jc.2009-1619 20080851
4. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, Liu FT, Lukic ML, Clin Immunol 2009 130 83 88 10.1016/j.clim.2008.08.024 18845486
5. Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro. Saksida T, Nikolic I, Vujicic M, Nilsson UJ, Leffler H, Lukic ML, Stojanovic I, Stosic-Grujicic S, J Cell Physiol 2013 228 1568 1576 10.1002/jcp.24318 23280610
6. Immune-mediated beta-cell destruction in vitro and in vivo-A pivotal role for galectin-3. Karlsen AE, Størling ZM, Sparre T, Larsen MR, Mahmood A, Størling J, Roepstorff P, Wrzesinski K, Larsen PM, Fey S, Nielsen K, Heding P, Ricordi C, Johannesen J, Kristiansen OP, Christensen UB, Kockum I, Luthman H, Nerup J, Pociot F, Biochem Biophys Res Commun 2006 344 406 415 10.1016/j.bbrc.2006.03.105 16600178
7. Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. Pang J, Rhodes DH, Pini M, Akasheh RT, Castellanos KJ, Cabay RJ, Cooper D, Perretti M, Fantuzzi G, PLoS One 2013 8 57915 10.1371/journal.pone.0057915 23451284
8. Galectin-3 deficiency accelerates high-fat diet induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Pejnovic N, Pantic J, Jovanovic I, Radosavljevic G, Milovanovic M, Nikolic I, Zdravkovic NS, Djukic AL, Arsenijevic NN, Lukic ML, Diabetes 2013 62 1932 1944 10.2337/db12-0222 23349493
9. Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T, Diabetes Res Clin Pract 2002 55 65 85 10.1016/S0168-8227(01)00365-5 11755481
10. The test meal A:A pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. Yoshino G, Tominaga M, Hirano T, Shiba T, Kashiwagi A, Tanaka A, Tada N, Onuma T, Egusa G, Kuwashima M, Sanke T, Oikawa S, Honda K, Tachikawa T, J Jpn Diabetes Soc 2006 49 361 371
11. Long-term miglitol administration suppresses postprandial glucose-dependent insulinotropic polypeptide secretion. Sumi K, Ohkura T, Yamamoto N, Fujioka Y, Matsuzawa K, Izawa S, Shiochi H, Kinoshita H, Ohkura H, Kato M, Yamamoto K, Taniguchi SI, Diabetol Int 2013 4 190 196 10.1007/s13340-013-0116-0
12. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study. Ohkura T, Inoue K, Fujioka Y, Nakanishi R, Shiochi H, Sumi K, Yamamoto N, Matsuzawa K, Izawa S, Ohkura H, Kato M, Yamamoto K, Taniguchi SI, BMC Res Notes 2013 6 453 10.1186/1756-0500-6-453 24215809
13. Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society, "International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H, J Diabetes Invest 2012 3 39 40 10.1111/j.2040-1124.2012.00207.x
14. National Institutes of Diabetes and Digestive and Kidney Diseases, the HbA1c converter, [article online] 1999 Available from http://www.ngsp.org/convert1.asp
15. Glucose clamp technique: a method for quantifying insulin secretion and resistance. DeFronzo RA, Tobin JD, Andres R, Am J Physiol 1979 237 214 223
16. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Kawamori R, Matsuhisa M, Kinoshita J, Mochizuki K, Niwa M, Arisaka T, Ikeda M, Kubota M, Wada M, Kanda T, Ikebuchi M, Tohdo R, Yamasaki Y, Diabetes Res Clin Pract 1998 41 35 43 10.1016/S0168-8227(98)00056-4 9768370
17. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, Kinoshita J, Ooka A, Kumashiro N, Igarashi Y, Kyogoku S, Maehara T, Kawasumi M, Hirose T, Kawamori R, J Clin Endocrinol Metab 2005 90 3191 3196 10.1210/jc.2004-1959 15769987
18. - 20/(fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Ohkura T, Shiochi H, Fujioka Y, Sumi K, Yamamoto N, Matsuzawa K, Izawa S, Kinoshita H, Ohkura H, Kato M, Taniguchi SI, Yamamoto K, Cardiovasc Diabetol 2013 12 21 10.1186/1475-2840-12-21 23339473
19. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Inohara H, Segawa T, Miyauchi A, Yoshii T, Nakahara S, Raz A, Maeda M, Miyoshi E, Kinoshita N, Yoshida H, Furukawa M, Takenaka Y, Takamura Y, Ito Y, Taniguchi N, Biochem Biophys Res Commun 2008 376 605 610 10.1016/j.bbrc.2008.09.041 18809382
20. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, Diabetologia 1985 28 412 419 10.1007/BF00280883 3899825
21. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Matsuda M, DeFronzo RA, Diabetes Care 1999 22 1462 1470 10.2337/diacare.22.9.1462 10480510
22. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. Seltzer HS, Allen EW, Herron AL Jr, Brennan MT, J Clin Invest 1967 46 323 335 10.1172/JCI105534 6023769
23. Interleukin-10 prevents diet induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, Friedline RH, Kurt-Jones E, Finberg R, Fischer MA, Granger EL, Norbury CC, Hauschka SD, Philbrick WM, Lee CG, Elias JA, Kim JK, Diabetes 2009 58 2525 2535 10.2337/db08-1261 19690064
24. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S, Biochem Biophys Res Commun 2001 280 1183 1188 10.1006/bbrc.2001.4256 11162652
25. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, Taurino M, Serino M, Marano G, Federici M, Pricci F, Pugliese G, Arterioscler Thromb Vasc Biol 2009 29 831 836 10.1161/ATVBAHA.109.186791 19359660